Inflammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer (LABC) that effects approximately 5% of women with breast cancer annually in the USA. It is a clinically and pathologically distinct form of LABC that is particularly fast growing, invasive, and angiogenic. Nearly all women have lymph node involvement at the time of diagnosis, and approximately 36% have gross distant metastases. Despite recent advances in multimodality treatments, the prognosis of patients with IBC is poor, with a median disease-free survival of less than 2.5 years. Recent work on the genetic determinants that underlie the IBC phenotype has led to the identification of genes that are involved in the development and progression of this disease. This work has been aided by the establishment of primary human cell lines and animal models. These advances suggest novel targets for future interventions in the diagnosis and treatment of IBC.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Lee BJ, Tannenbaum NE: Inflammatory carcinoma of the breast: a report of twenty-eight cases from the breast clinic of Memorial Hospital. Surg Gynecol Obstet. 1924, 39: 580-595.
Haagensen CD: . Diseases of the Breast. Philadelphia: WB Saunders,. 1986
Piera JM, Alonso MC, Ojeda MB: Locally advanced breast cancer with inflammatory component: a clinical entity with a poor prognosis. Rad Oncol. 1986, 7: 199-204. CrossRef
Stocks LH, Patternson FM: Inflammatory carcinoma of the breast. Surg Gynecol Obstet. 1976, 143: 885-889. PubMed
Rosen PP: . Rosen's Breast Pathology. Philadelphia: Lippincott-Raven,. 1996
Haagensen CD, Stout AP: Carcinoma of the breast II - criteria of operability. Ann Surg. 1942, 118: 859-870. CrossRef
Baclesse F: Roentgen therapy alone as the method of treatment of cancer of the breast. AJR Am J Roentgenol. 1949, 62: 311-319.
DeLena M, Zucali R, Viganotti G: Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol. 1978, 1: 53-59. CrossRef
Rouesse S, Sarrazin D, Mouriesse H, Le Chevalier T, Arriagada R, Spielmann M, Papacharalambous A, May-Levin F: Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol. 1986, 4: 1765-1771. PubMed
Swain SM, Sorace RA, Bagley CS, Danforth DN, Bader J, Wesley MN, Steinberg SM, Lippman ME: Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res. 1987, 47: 3889-3894. PubMed
Merajver SD, Weber BL, Cody R, Zhang D, Strawderman M, Calzone KA, LeClaire V, Levin A, Irani J, Halvie M, August D, Wicha M, Lichter A, Pierce LJ: Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience. J Clin Oncol. 1997, 15: 2873-2881. PubMed
Abner AL, Recht A, Eberlein T, Come S, Shulman L, Hayes D, Connolly JL, Schnitt SJ, Silver B, Harris JR: Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol . 1993, 11: 44-48. PubMed
Jaiyesimi I, Buzdar A, Hortobagyi G: Inflammatory breast cancer: a review. J Clin Oncol. 1992, 10: 1014-1024. PubMed
Kaufman M: Review of known prognostic variables. Results Probl Cell Differ. 2000, 140: 77-87.
Guerin M, Sheng ZM, Andrieu N, Riou G: Strong association between c- myb and oestrogen-receptor expression in human breast cancer. Oncogene. 1990, 5: 131-135. PubMed
Blondal JA, Benchimol S: The role of p53 in tumor progression. Semin Cancer Biol. 1994, 5: 177-186. PubMed
Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989, 342: 705-708. 10.1038/342705a0. CrossRefPubMed
van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, Merajver SD: A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res. 1999, 5: 2511-2519. PubMed
Hwa V: The IGFBP superfamily. Growth Hormone IGF Res . 1999, 9: 299-307. 10.1054/ghir.1999.0123. CrossRef
Ridley A: The GTP-binding Protein Rho. Int J Biochem Cell Biol. 29: 1225-1229.
Prendergast C, Khosravi-Far R, Solski P, Kurzawa H, Lebowitz P, Der C: Critical role of Rho in cell transformation by oncogenic Ras. Oncogene. 1995, 10: 2289-2296. PubMed
Clemons D: Role of insulin-like growth factor binding proteins in controling IGF actions. Mol Cell Endocrinol. 1998, 140: 19-24. 10.1016/S0303-7207(98)00024-0. CrossRef
Burger A, Zhang X, Li H, Ostrowski J, Beatty B, Venanzoni M, Papas T, Seth A: Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. Oncogene. 1998, 16: 2459-2467. 10.1038/sj/onc/1201772. CrossRefPubMed
Sprenger CC, Damon SE, Hwa V, Rosenfeld R, Plymate SR: Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor supressor for prostate cancer. Cancer Res. 1999, 59: 2370-2375. PubMed
Achen M, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks A, Alitalo K, Stacker S: Vascular enothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flt 1) and VEGF receptor 3 (Flt 4). Proc Natl Acad Sci USA. 1998, 95: 548-553. 10.1073/pnas.95.2.548. CrossRefPubMedPubMedCentral
Alpaugh ML, Tomlinson JS, Shao Z-M, Barsky SH: A novel human xenograft model of inflammatory breast cancer. Cancer Res. 1999, 59: 5079-5084. PubMed
- Molecular biology of breast cancer metastasis Inflammatory breast cancer: clinical syndrome and molecular determinants
Celina G Kleer
Kenneth L van Golen
Sofia D Merajver
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II